CLS – Cellectis S.A.

Latest News & Stock Analysis

Cellectis S.A. (CLS) is a pioneering gene editing company focused on developing innovative allogeneic CAR-T cell therapies for cancer. Utilizing its proprietary TALEN® technology, Cellectis engineers off-the-shelf CAR-T therapies designed to target various hematological malignancies and solid tumors. This innovative approach aims to provide accessible and scalable cancer treatments, distinguishing Cellectis in the competitive biotechnology market. Investors interested in biotechnology stocks and gene editing technologies will find Cellectis a compelling investment opportunity. Stay updated with the latest news on CLS, market trends, and in-depth stock analysis to make informed investment decisions.

Celestica: Powering Growth, But Is the Price Right?
CLS

Celestica: Powering Growth, But Is the Price Right?

by | 20/04/2025 08:00 AM | CLS

⚡ Celestica's operating profit nearly doubled in the last year, continuing an upward trend since 2020.

💰 The company boasts a solid balance sheet (1.5x solvency ratio) and record free cash flow per share ($2.50 in 2024, up ~50%).

📉 After a significant price surge, the stock retraced 50% to a support level near $78; currently trading at 27 times earnings, suggesting waiting for a pullback might offer a more attractive valuation.

Read more!